Skip to main content
. 2017 Aug 24;8(62):104867–104876. doi: 10.18632/oncotarget.20452

Figure 5. Keap1 silence by shRNA or miR-200a protects primary human osteoblasts from Dex.

Figure 5

Primary human osteoblasts were transfected with Keap1 shRNA (“Sequ1”) or miR-200a Vector (“miR-200a-Vec”) as described; Relative expression of miR-200a-3p (A), Keap1 mRNA (B) and Keap1/Nrf2 protein (C), and quantified in (D) were shown; Cells were also treated with/out Dex (1 μM) for 48 hours, cell viability (CCK-8 OD, (E) and cell death (LDH release, (F) were tested. “C” stands for no Dex treatment. “Ctrl” stands for un-transfected control cells. Data were expressed as mean ± SD (n=5). * p <0.05 vs. “Ctrl”.